Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Ellen Kapiteijn, Matteo Carlino, Valentina Boni, Delphine Loirat, Frank Speetjens, John Park, Emiliano Calvo, Richard Carvajal, Marta Nyakas, Juan Gonzalez-Maffe, Xu Zhu, Ramu Thiruvamoor, Padmaja Yerramilli-Rao, Sophie Piperno-Neumann | ||||||||||||
Title | A Phase I trial of LXS196, a novel PKC inhibitor for metastatic uveal melanoma | ||||||||||||
|
|||||||||||||
URL | https://www.abstractsonline.com/pp8/#!/6812/presentation/9883 | ||||||||||||
Abstract Text | AACR Annual Meeting 2019, Abstract CT068 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
IDE196 | LXS196|IDE 196|IDE-196|Darovasertib | PKC Inhibitor (Pan) 11 | IDE196 (LXS196) is an inhibitor of protein kinase C (PKC), thereby blocking signaling pathways triggered by PKC, which may result in cell cycle arrest and apoptosis (AACR Annual Meeting 2019, Abstract CT068). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|